Sabin Vaccine Institute Receives Award to Develop Develop Ebola Sudan and Marburg Vaccines
The Sabin Vaccine Institute (Sabin) has announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services. Under the terms of this agreement, the full program is expected to advance development of clinical-stage monovalent vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.
Ebola Sudan and Marburg are among the world’s deadliest viruses, causing hemorrhagic fever with subsequent death in an average of 50 percent of cases [1,2]. A closely related strain, Ebola Zaire, has caused more than 2,000 deaths in the past year during the ongoing outbreak in the Democratic Republic of Congo (DRC) , leading the World Health Organization to declare it a Public Health Emergency of International Concern . With Ebola Sudan and Marburg’s own history of outbreaks and their potential for future devastating outbreaks, preventative measures are overdue to protect civilian populations, military personnel, first responders, healthcare workers and laboratory workers, both in the United States and abroad, against these emerging infectious diseases.
“Vaccines are the most effective shield we can use against Ebola and Marburg viruses, both of which have a long history of deadly outbreaks,” said Sabin Chief Executive Officer Amy Finan. “In the years ahead, we hope to make available the reliable protection every man, woman and child needs to defend themselves against these life-threatening diseases.”
The BARDA funding will enable Sabin to advance the investigational Ebola Sudan and Marburg vaccines using the ChAd3-based platform recently licensed under an agreement between GSK and Sabin. Building on the immunogenicity and safety demonstrated in recent Phase 1 clinical trials by the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, Sabin aims to advance the ChAd3 vaccines in pursuit of licensure and stockpiling. Under the terms of the agreement, the initial $20.5 million award supports process development and non-clinical activities. Additional non-clinical studies, as well as manufacturing of clinical material and Phase 2 clinical trials in the United States and Africa, may be supported by $107.5 million in additional funding.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C000555.